Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Breast Cancer, Cardiotoxicity
Interventions
antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers
Other · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Terminated Not applicable Interventional Results available

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

NCT01953874
Conditions
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Interventions
MV ASV, Optimized Medical Treatment
Device · Drug
Lead sponsor
ResMed
Industry
Eligibility
21 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Huntsville, Alabama • Los Angeles, California • Denver, Colorado + 11 more
Conditions
Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
Interventions
Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
Device · Drug
Lead sponsor
Nuwellis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
38
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure Acute, Cardiovascular Diseases
Interventions
Metolazone Oral Tablet, Chlorothiazide Injection
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Heart Failure, Volume Overload
Interventions
Direct Sodium Removal Infusate 2.0
Drug
Lead sponsor
Sequana Medical N.V.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

NCT00689819
Conditions
Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions
Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Behavioral · Drug
Lead sponsor
Wayne State University
Other
Eligibility
35 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Completed Phase 4 Interventional Accepts healthy volunteers

Weight-Based Torsemide Dosing in Subjects With Heart Failure

NCT03187509
Conditions
Heart Failure
Interventions
Torsemide, Standard Outpatient Heart Failure Management
Drug · Other
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure
Interventions
LUS-guided strategy-of-care, Usual Care, Intravenous Loop Diuretic, Vasodilator, Non invasive Ventilation (NIV)
Other · Drug · Device
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Indianapolis, Indiana • Detroit, Michigan • Cleveland, Ohio + 2 more
Conditions
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease
Interventions
Blood pressure, Urine protein
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 17 Years
Enrollment
20,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acute Decompensated Heart Failure
Interventions
Furosemide plus Chlorothiazide, Furosemide
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systolic Blood Pressure Intervention Trial

NCT01206062
Conditions
Hypertension
Interventions
Intensive control of SBP, Standard control of SBP
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years and older
Enrollment
9,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Not applicable Interventional Results available

Baroreflex Activation Therapy for Heart Failure

NCT02627196
Conditions
Heart Failure
Interventions
BAROSTIM NEO® System, Medical Management
Device · Drug
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years and older
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
88
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 74 more
Conditions
Hypertension (HTN)
Interventions
Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Conditions
Heart Failure
Interventions
Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide), IV Chlorothiazide
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Heart Failure
Interventions
Spironolactone 100mg, Spironolactone 25mg
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional

BAROSTIM® Hope for Heart Failure Study

NCT01720160
Conditions
Heart Failure
Interventions
BAROSTIM NEO® System, Standard of care medical managment therapy for heart failure
Device · Other
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
23
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 20 more
Conditions
Medication Absorption
Interventions
Water, Parmalat™ Whole Milk, Similac Pro-Advance™, Ensure Plus™, Furosemide 20 MG
Dietary Supplement · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Congestive Heart Failure, Renal Insufficiency
Interventions
Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule
Drug
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
End Stage Renal Failure on Dialysis
Interventions
Hemodialysis, Patiromer Oral Product
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
Interventions
Aquadex Smartflow® System, IV Loop Diuretics
Device · Drug
Lead sponsor
Nuwellis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
Tucson, Arizona • Long Beach, California • San Diego, California + 10 more
Conditions
Heart Failure
Interventions
Tolvaptan, placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Interventions
Furosemide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Hypertension
Interventions
Loop diuretics, thiazides, dihydropyridines, Telmisartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years and older
Enrollment
40,048 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts